• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ISPOR's Initiative on US Value Assessment Frameworks: A Missed Opportunity for ISPOR and Patients.

作者信息

Perfetto Eleanor M

机构信息

National Health Council, Washington, DC, USA; University of Maryland, School of Pharmacy, Department of Pharmaceutical Health Services Research, Baltimore, MD.

出版信息

Value Health. 2018 Feb;21(2):169-170. doi: 10.1016/j.jval.2017.12.002.

DOI:10.1016/j.jval.2017.12.002
PMID:29477396
Abstract
摘要

相似文献

1
ISPOR's Initiative on US Value Assessment Frameworks: A Missed Opportunity for ISPOR and Patients.药物经济学与结果研究国际协会（ISPOR）的美国价值评估框架倡议：ISPOR和患者错失的机遇。
Value Health. 2018 Feb;21(2):169-170. doi: 10.1016/j.jval.2017.12.002.
2
ISPOR's Initiative on US Value Assessment Frameworks: An Industry Perspective.药物经济学与结果研究国际协会（ISPOR）关于美国价值评估框架的倡议：行业视角
Value Health. 2018 Feb;21(2):173-175. doi: 10.1016/j.jval.2017.12.001.
3
ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics.药物经济学与结果研究国际协会（ISPOR）关于美国价值评估框架的倡议：探寻健康经济学的作用。
Value Health. 2018 Feb;21(2):171-172. doi: 10.1016/j.jval.2017.12.003.
4
ISPOR's Initiative on US Value Assessment Frameworks: The Use of Cost-Effectiveness Research in Decision Making among US Insurers.国际药效经济学与结果研究协会（ISPOR）关于美国价值评估框架的倡议：成本效益研究在美国保险公司决策中的应用。
Value Health. 2018 Feb;21(2):166-168. doi: 10.1016/j.jval.2017.12.004.
5
A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].一种用于美国价值评估框架的卫生经济学方法——国际药物经济学与结果研究协会（ISPOR）特别工作组报告的总结与建议[7]
Value Health. 2018 Feb;21(2):161-165. doi: 10.1016/j.jval.2017.12.009.
6
An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].价值、视角与决策背景概述——一种卫生经济学方法：ISPOR 特别工作组报告 [2]
Value Health. 2018 Feb;21(2):124-130. doi: 10.1016/j.jval.2017.12.006.
7
Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].目标、预算、阈值与机会成本——一种卫生经济学方法：一份药物经济学与结果研究协会（ISPOR）特别工作组报告[4]
Value Health. 2018 Feb;21(2):140-145. doi: 10.1016/j.jval.2017.12.008.
8
Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].近期美国价值框架综述——一种卫生经济学方法：一份药物经济学与结果研究协会（ISPOR）特别工作组报告[6]
Value Health. 2018 Feb;21(2):155-160. doi: 10.1016/j.jval.2017.12.011.
9
A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].美国价值评估框架的健康经济学方法——引言：一份ISPOR特别工作组报告[1]
Value Health. 2018 Feb;21(2):119-123. doi: 10.1016/j.jval.2017.12.012.
10
Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].医疗保健价值的定义要素——一种卫生经济学方法：一份ISPOR特别工作组报告[3]
Value Health. 2018 Feb;21(2):131-139. doi: 10.1016/j.jval.2017.12.007.

引用本文的文献

1
Treatment goals for rheumatoid arthritis: patient engagement and goal collection.类风湿关节炎的治疗目标：患者参与和目标收集。
J Comp Eff Res. 2023 May;12(5):e220097. doi: 10.57264/cer-2022-0097. Epub 2023 Mar 28.
2
Patient and Caregiver Views on Measures of the Value of Health Interventions.患者及护理人员对健康干预措施价值衡量标准的看法。
Patient Prefer Adherence. 2022 Dec 20;16:3383-3392. doi: 10.2147/PPA.S390227. eCollection 2022.
3
Health-related quality-of-life and health-utility reporting in critical care.重症监护中与健康相关的生活质量及健康效用报告
World J Crit Care Med. 2022 Jul 9;11(4):236-245. doi: 10.5492/wjccm.v11.i4.236.
4
Evaluating the development, woman-centricity and psychometric properties of maternity patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs): A systematic review protocol.评价产妇患者报告结局测量（PROMs）和患者报告体验测量（PREMs）的发展、以女性为中心和心理测量学特性：系统评价方案。
BMJ Open. 2022 Feb 10;12(2):e058952. doi: 10.1136/bmjopen-2021-058952.
5
Proposal for capturing patient experience through extended value frameworks of health technologies.通过扩展健康技术的价值框架来获取患者体验的建议。
J Manag Care Spec Pharm. 2021 Jul;27(7):936-947. doi: 10.18553/jmcp.2021.27.7.936.
6
Value-based drug pricing in the Biden era: Opportunities and prospects.拜登时代基于价值的药品定价：机遇与前景。
Health Serv Res. 2021 Dec;56(6):1093-1099. doi: 10.1111/1475-6773.13686. Epub 2021 Jun 3.
7
Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports.利益相关者对ICER证据报告草案公众意见的参与情况分析。
Am Health Drug Benefits. 2020 Sep;13(4):136-142.
8
HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.在美国进行 HTA：美国的 ICER 与英国英格兰和威尔士的 NICE 比较。
J Manag Care Spec Pharm. 2020 Sep;26(9):1162-1170. doi: 10.18553/jmcp.2020.26.9.1162.
9
The Importance of Collaboration in Pursuit of Patient-Centered Value Assessment.追求以患者为中心的价值评估中合作的重要性。
Patient. 2021 Jul;14(4):381-384. doi: 10.1007/s40271-020-00446-3.
10
The promise of Immuno-oncology: implications for defining the value of cancer treatment.免疫肿瘤学的前景：对定义癌症治疗价值的影响。
J Immunother Cancer. 2019 May 17;7(1):129. doi: 10.1186/s40425-019-0594-0.